Clin2
NCT07249632Possibly a fitRecruiting

Study of Telitacicept for Eye Muscle Weakness from Myasthenia Gravis

Myasthenia Gravis, Ocular

Treatments studied

Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.

This trial tests a new drug, telitacicept, for people with myasthenia gravis that only affects the eyes (ocular myasthenia gravis). The goal is to see if it can improve symptoms like droopy eyelids or double vision.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
120 people
Ages
12 years to 80 years
Study type
Interventional

Who can take part

  • You are between 12 and 80 years old.
  • You weigh at least 30 kg (about 66 pounds).
  • You have been diagnosed with myasthenia gravis that only affects your eyes (MGFA Type I).
  • You are on a stable treatment plan for your condition.
  • You do not have other uncontrolled medical conditions or infections.
  • You are not allergic to human-derived biologic medicines.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05067348Recruiting· Phase 2
Tocilizumab for generalized myasthenia gravis symptoms

This trial tests whether tocilizumab can improve symptoms and safety in people with generalized myasthenia gravis (MG) who already take standard MG treatments. It may help if your weakness is still significant despite current therapy.

Beijing, Beijing Municipality
NCT07298928Not yet recruiting
Telitacicept for children with ocular myasthenia gravis

This trial is testing a new drug called telitacicept for children with ocular myasthenia gravis (eye muscle weakness). It aims to see if the drug is safe and effective when added to standard treatments.

Shenzhen, Guangdong
NCT06456580Recruiting· Phase 3
Telitacicept for generalized myasthenia gravis

This trial tests a new medication called Telitacicept for people with generalized myasthenia gravis (gMG). The goal is to see if it can reduce muscle weakness and improve daily function. You may be able to join if you have moderate to severe symptoms and have not had recent thymoma or other serious health issues.

Scottsdale, Arizona
NCT06827587Not yet recruiting
Efgartigimod then Telitacicept for Myasthenia Gravis

This trial tests whether taking two drugs one after the other—efgartigimod followed by telitacicept—is safe and effective for people with generalized myasthenia gravis. It may offer a new treatment option if standard therapy isn't enough.

NCT06723548Not yet recruiting· Phase 4
Telitacicept and low-dose steroids for hard-to-treat myasthenia gravis

This trial tests a new medicine called telitacicept combined with low-dose steroids for people with hard-to-treat myasthenia gravis. The goal is to see if this combination can better control symptoms that haven't improved with standard treatments.

NCT07355257Not yet recruiting· Phase 2/Phase 3
Telitacicept for inflammatory muscle disease (myositis) trial

This trial tests an investigational drug called Telitacicept for people with inflammatory myopathies (muscle inflammation). It aims to see if the drug can help when standard treatments haven't worked well.

Hear when a new Myasthenia Gravis, Ocular trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.